S. Korea Expects 3 More Homegrown COVID-19 Treatments in H1

SEOUL, Feb. 13 (Korea Bizwire) — Three homegrown treatments for the novel coronavirus are expected to receive approval as early as the first half of this year as the country speeds up the approval process amid the pandemic. Last week, the country’s drug safety agency approved pharmaceutical giant Celltrion Inc.’s CT-P59, an anti-COVID-19 monoclonal antibody [...]